Corrigendum to “Human umbilical cord mesenchymal stem cells secretome and nanoemulsion propolis combination ameliorate osteoclastogenesis in lipopolysaccharide-induced osteolysis in hyperglycemia rats” [J Dent Sci] 20 (2025) 2181–2188

In the original publication of this article, there was an error in the placement of Figure 1 (panels A. NFATc1, B. Sclerostin, C. RANK, D. RANKL, E. OPG). Due to a human error during the layouting process, the figure panels were incorrectly positioned relative to their corresponding captions and text references. This error has now been corrected. This correction does not alter the scientific findings, data interpretation, or conclusions of the paper.

Figure 1.

Effect of NEP and HUCMSCS combination on LPS-induced osteolysis in hyperglycemia condition. Image of the NFATc-1 (A), sclerostin (B), RANK (C), RANKL (D), and OPG (E) immunohistochemistry analysis with DAB staining and counterstained with hematoxylin. NFATc-1, sclerostin, RANK, RANKL, and OPG-positive cells were stained brown at 100×, 400×, and 1000× magnification. The statistical significance of differences was determined by t-tests and one-way analysis of variance (ANOVA) with significance set at p-value ≤0.05. Results are expressed as the mean ± SEM. HUCMSCS, human umbilical cord mesenchymal stem cells secretome; LPS, lipopolysaccharide; NEP, nanoemulsion propolis extract; NFATc1, nuclear factor associated T-cell-1; OPG, osteoprotegrin; PBS, phosphate-buffered saline; RANK, receptor activator nuclear kappa beta; RANKL, receptor activator nuclear kappa beta ligand.